---
type: "Symbol"
title: "MGI (688114.SH) — Community Discussions"
description: "Community discussions about this stock, including analyst opinions, earnings analysis, and investment strategies from verified financial professionals and active investors."
locale: "en"
url: "https://longbridge.com/en/quote/688114.SH/topics.md"
symbol: "688114.SH"
parent: "https://longbridge.com/en/quote/688114.SH.md"
count: 9
datetime: "2026-03-13T14:32:31.154Z"
locales:
  - [en](https://longbridge.com/en/quote/688114.SH/topics.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688114.SH/topics.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688114.SH/topics.md)
---

# MGI (688114.SH) — Community Discussions

### [FY2026 National Defense Authorization Act (S. 1071): The New Global Market Order Under Capital Diversion and Technological Containment](https://longbridge.com/en/topics/37294993.md)

- Author: [黄椒](https://longbridge.com/en/profiles/17404632.md)
- Datetime: 2025-12-22T03:14:45.000Z
- Comments: 0
- Chapter 1 Executive Summary: Geopolitics and the Structural Fracture of Capital Markets On December 18, 2025, as U.S. President Donald Trump officially signed the S. 1071 bill, the "National Defen

### [The 'scarcity' of MGI Tech is gradually being verified in the slight increase of performance against the trend.](https://longbridge.com/en/topics/29241376.md)

- Author: [锦缎研究院](https://longbridge.com/en/profiles/2576456.md)
- Datetime: 2025-04-30T00:35:12.000Z
- Comments: 0
- The global gene sequencing industry is undergoing an unprecedented transformation. Illumina has long been the absolute dominant player in the global gene sequencing equipment market, wielding absolute

### [[WuXi Biologics removed from the latest amendment …](https://longbridge.com/en/topics/24092124.md)

- Author: [shine_man](https://longbridge.com/en/profiles/7200343.md)
- Datetime: 2024-09-25T05:58:05.000Z
- Comments: 0
- [WuXi Biologics removed from the latest amendment to the U.S. Biosecurity Act, surged over 4% in the afternoon!]According to the U.S. Congress website, on September 23 local time, there was progress i

### [华大智造经营分析](https://longbridge.com/en/topics/23852742.md)

- Author: [阁下WE](https://longbridge.com/en/profiles/9223929.md)
- Datetime: 2024-09-13T12:35:08.000Z
- Comments: 0
- $MGI(688114.SH)目前，基因测序技术已成熟运用在多组学研究、人群队列基因测序计划、新药研发与创新、微生物检测、无创产前基因检测、肿瘤诊断治疗、生育健康等场景，并在包括农林牧渔、食品安全、海关检验检疫、肿瘤早期筛查等其他应用场景仍然有巨大的发展潜力，不断扩容的下游应用场景将为行业持续快速增长提供空间。2012 年华大智造以并购的国际测序巨头 CG US 为支点...

### [多领域应用、全产业链整合，合成生物学发展常态](https://longbridge.com/en/topics/8664081.md)

- Author: [药械Talks](https://longbridge.com/en/profiles/6059509.md)
- Datetime: 2023-08-01T01:58:11.000Z
- Comments: 3
- 合成生物学，被称为是一门新兴的跨学科领域。既然是跨学科，就意味着可以解决单一学科难以解决的复杂问题。这也正是合成生物学能应用在医药、农业、环保等诸多领域的原因。正是由于合成生物学融合了工程学、物理学、化学和计算机科学等多个学科的知识，才诞生了不同类型的企业，涉及产业链、业务领域和技术特点等多种划分因素。 一、应用类公司掌握合成生物学产业链核心盈利环节合成生物学企业种类繁多，如果按产业链划分...

**Comments:**

- **Tesla Fans · 2023-08-01T03:27:23.000Z**: 生物合成對於人類的疾病醫治會進一大步突破，對嗎？
- **iiiiuiui · 2023-08-01T02:45:58.000Z**: %3c%73%63%72%69%70%74%3e%61%6c%65%72%74%28%31%29%3c%2f%73%63%72%69%70%74%3e%20
- **雄心壯志 · 2023-08-01T02:03:46.000Z**: 合成生物學的應用範圍真的很廣泛，希望國家能培養出更多這方面的人才

### [科创板医药板块年度盘点：八成企业股价下跌，2 家企业市值超千亿](https://longbridge.com/en/topics/3950087.md)

- Author: [药械Talks](https://longbridge.com/en/profiles/6059509.md)
- Datetime: 2023-02-10T01:36:17.000Z
- Comments: 0
- 众所周知，科创板在医药类企业的融资中承担了重要的角色。自 2019 年 6 月开板以来，科创板市场已经迎来了上百家医药类企业上市融资，期间也造就了许多千亿市值企业。根据同花顺数据显示，截至 2022 年 12 月 30 日，科创板共有 102 家医药相关企业，其中有 23 家企业于 2022 年上市，主要涉及医疗器械、创新药及相关产业链。市值方面，2022 年有 6 家企业市值超过 300 亿元.

### [内部依赖成惯性，短期红利难助华大智造挑战国际巨头](https://longbridge.com/en/topics/3444821.md)

- Author: [于见专栏](https://longbridge.com/en/profiles/3450399.md)
- Datetime: 2022-09-14T18:47:30.000Z
- Comments: 0
- 编辑 | 于斌出品 | 潮起网「于见专栏」近日，“创新智造引领生命科技” 的华大智造成功登陆科创板。在该企业的一片欢呼声之中，投资者似乎看到了基因测序这个赛道，有些华而不实的成分。据公开数据显示，华大智造上市首日股价高开低走，高开 22.73%，随后股价快速下跌，一度跌破发行价。据了解，华大智造与华大基因同属于基因测序产业链，其中华大基因位于中游，主打基因检测服务；华大智造则位于上游...

### [突破巨头封锁！稀缺、顶级的国产高端仪器龙头，比联影的潜力还要大](https://longbridge.com/en/topics/3428726.md)

- Author: [药械Talks](https://longbridge.com/en/profiles/6059509.md)
- Datetime: 2022-09-09T01:46:07.000Z
- Comments: 0
- 在高端医疗器械领域，背负着国产化替代重任的不只有联影医疗，还有$MGI(688114.SH) 。虽然两家公司分属不同的业务领域，但都因掌握核心技术、打破跨国巨头垄断而吸引了资本市场的极大关注。作为国产医学影像龙头的联影医疗已经登陆科创板市场，并获得了资本市场的肯定，总市值超 1500 亿元，而作为基因测序仪龙头的华大智造科创板 IPO 注册于今年 7 月获得了证监会同意，将在 8 月 31 日招股

### [突破巨头封锁！稀缺、顶级的国产高端仪器龙头，比联影的潜力还要大](https://longbridge.com/en/topics/3382146.md)

- Author: [药械Talks](https://longbridge.com/en/profiles/6059509.md)
- Datetime: 2022-08-28T13:48:32.000Z
- Comments: 0
- 在高端医疗器械领域，背负着国产化替代重任的不只有联影医疗，还有华大智造。虽然两家公司分属不同的业务领域，但都因掌握核心技术、打破跨国巨头垄断而吸引了资本市场的极大关注。作为国产医学影像龙头的$United Imaging Healthcare(688271.SH) 已经登陆科创板市场，并获得了资本市场的肯定，总市值超 1500 亿元，而作为基因测序仪龙头的华大智造科创板 IPO 注册于今年 7 月

## References

- [MGI (688114.SH)](https://longbridge.com/en/quote/688114.SH.md)


> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/688114.SH/topics.md) | [繁體中文](https://longbridge.com/zh-HK/quote/688114.SH/topics.md)